Publikation

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

Wissenschaftlicher Artikel/Review - 23.05.2010

Bereiche
PubMed
DOI

Zitation
Rao S, Beadman C, Kurek R, Archer C, Wilke H, Valladares-Ayerbes M, Ruhstaller T, Gilligan D, Sumpter K, Cunningham D, Starling N, Oates J. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010; 21:2213-9.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Ann Oncol 2010; 21
Veröffentlichungsdatum
23.05.2010
eISSN (Online)
1569-8041
Seiten
2213-9
Kurzbeschreibung/Zielsetzung

Clinical data showed promising antitumour activity with feasible tolerability for matuzumab plus epirubicin, cisplatin and capecitabine (ECX) chemotherapy in untreated advanced oesophago-gastric (OG) cancer. The aim was to evaluate the efficacy of matuzumab plus ECX versus ECX alone.